vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and SouthState Bank Corp (SSB). Click either name above to swap in a different company.
SouthState Bank Corp is the larger business by last-quarter revenue ($661.7M vs $360.9M, roughly 1.8× LivaNova PLC). SouthState Bank Corp runs the higher net margin — 34.1% vs 8.6%, a 25.6% gap on every dollar of revenue. Over the past eight quarters, SouthState Bank Corp's revenue compounded faster (37.4% CAGR vs 10.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
SouthState Bank, based in Winter Haven, Florida, is an American bank and a subsidiary of SouthState Corporation, a bank holding company. As of May 26, 2025, the company had 371 branches in South Carolina, North Carolina, Georgia, Florida, Alabama, Virginia, Colorado and Texas.
LIVN vs SSB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $661.7M |
| Net Profit | $30.9M | $225.8M |
| Gross Margin | 65.2% | — |
| Operating Margin | 11.8% | 15.1% |
| Net Margin | 8.6% | 34.1% |
| Revenue YoY | 12.1% | — |
| Net Profit YoY | -44.7% | 153.5% |
| EPS (diluted) | $0.57 | $2.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $661.7M | ||
| Q4 25 | $360.9M | $581.1M | ||
| Q3 25 | $357.8M | $599.7M | ||
| Q2 25 | $352.5M | $577.9M | ||
| Q1 25 | $316.9M | $544.5M | ||
| Q4 24 | $321.8M | $369.8M | ||
| Q3 24 | $318.1M | $351.5M | ||
| Q2 24 | $318.6M | $350.3M |
| Q1 26 | — | $225.8M | ||
| Q4 25 | $30.9M | $247.7M | ||
| Q3 25 | $26.8M | $246.6M | ||
| Q2 25 | $27.2M | $215.2M | ||
| Q1 25 | $-327.3M | $89.1M | ||
| Q4 24 | $55.9M | $144.2M | ||
| Q3 24 | $33.0M | $143.2M | ||
| Q2 24 | $16.3M | $132.4M |
| Q1 26 | — | — | ||
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 70.8% | — | ||
| Q2 24 | 68.7% | — |
| Q1 26 | — | 15.1% | ||
| Q4 25 | 11.8% | 54.3% | ||
| Q3 25 | 15.1% | 53.6% | ||
| Q2 25 | 15.4% | 48.8% | ||
| Q1 25 | 15.3% | 22.3% | ||
| Q4 24 | 11.5% | 50.7% | ||
| Q3 24 | 11.2% | 53.1% | ||
| Q2 24 | 12.6% | 49.3% |
| Q1 26 | — | 34.1% | ||
| Q4 25 | 8.6% | 42.6% | ||
| Q3 25 | 7.5% | 41.1% | ||
| Q2 25 | 7.7% | 37.2% | ||
| Q1 25 | -103.3% | 16.4% | ||
| Q4 24 | 17.4% | 39.0% | ||
| Q3 24 | 10.4% | 40.7% | ||
| Q2 24 | 5.1% | 37.8% |
| Q1 26 | — | $2.28 | ||
| Q4 25 | $0.57 | $2.47 | ||
| Q3 25 | $0.49 | $2.42 | ||
| Q2 25 | $0.50 | $2.11 | ||
| Q1 25 | $-6.01 | $0.87 | ||
| Q4 24 | $1.04 | $1.88 | ||
| Q3 24 | $0.60 | $1.86 | ||
| Q2 24 | $0.30 | $1.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $2.9B |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $9.0B |
| Total Assets | $2.6B | $68.0B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.9B | ||
| Q4 25 | $635.6M | — | ||
| Q3 25 | $646.1M | — | ||
| Q2 25 | $593.6M | — | ||
| Q1 25 | $738.4M | — | ||
| Q4 24 | $428.9M | — | ||
| Q3 24 | $346.4M | — | ||
| Q2 24 | $329.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — |
| Q1 26 | — | $9.0B | ||
| Q4 25 | $1.2B | $9.1B | ||
| Q3 25 | $1.2B | $9.0B | ||
| Q2 25 | $1.1B | $8.8B | ||
| Q1 25 | $1.0B | $8.6B | ||
| Q4 24 | $1.3B | $5.9B | ||
| Q3 24 | $1.3B | $5.9B | ||
| Q2 24 | $1.2B | $5.7B |
| Q1 26 | — | $68.0B | ||
| Q4 25 | $2.6B | $67.2B | ||
| Q3 25 | $2.6B | $66.0B | ||
| Q2 25 | $2.5B | $65.9B | ||
| Q1 25 | $2.6B | $65.1B | ||
| Q4 24 | $2.5B | $46.4B | ||
| Q3 24 | $2.5B | $46.1B | ||
| Q2 24 | $2.5B | $45.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | — |
| Free Cash FlowOCF − Capex | $50.2M | — |
| FCF MarginFCF / Revenue | 13.9% | — |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $82.4M | $232.1M | ||
| Q3 25 | $85.1M | $122.4M | ||
| Q2 25 | $62.9M | $72.6M | ||
| Q1 25 | $24.0M | $-126.3M | ||
| Q4 24 | $78.7M | $354.3M | ||
| Q3 24 | $51.0M | $-246.8M | ||
| Q2 24 | $43.4M | $126.8M |
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $215.5M | ||
| Q3 25 | $62.2M | $101.7M | ||
| Q2 25 | $47.8M | $52.5M | ||
| Q1 25 | $13.2M | $-139.1M | ||
| Q4 24 | $68.3M | $340.9M | ||
| Q3 24 | $32.8M | $-254.2M | ||
| Q2 24 | $31.2M | $117.3M |
| Q1 26 | — | — | ||
| Q4 25 | 13.9% | 37.1% | ||
| Q3 25 | 17.4% | 17.0% | ||
| Q2 25 | 13.6% | 9.1% | ||
| Q1 25 | 4.2% | -25.5% | ||
| Q4 24 | 21.2% | 92.2% | ||
| Q3 24 | 10.3% | -72.3% | ||
| Q2 24 | 9.8% | 33.5% |
| Q1 26 | — | — | ||
| Q4 25 | 8.9% | 2.9% | ||
| Q3 25 | 6.4% | 3.5% | ||
| Q2 25 | 4.3% | 3.5% | ||
| Q1 25 | 3.4% | 2.4% | ||
| Q4 24 | 3.2% | 3.6% | ||
| Q3 24 | 5.7% | 2.1% | ||
| Q2 24 | 3.8% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.67× | 0.94× | ||
| Q3 25 | 3.18× | 0.50× | ||
| Q2 25 | 2.32× | 0.34× | ||
| Q1 25 | — | -1.42× | ||
| Q4 24 | 1.41× | 2.46× | ||
| Q3 24 | 1.55× | -1.72× | ||
| Q2 24 | 2.65× | 0.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
